cancer cell

(Cell Press) Scientists have identified some of the elusive downstream molecules that play a critical role in the development and progression of familial breast cancer.

The research, published by Cell Press in the Oct. 10 issue of the journal Molecular Cell, also identifies a compound found in grapes and red wine as an excellent candidate for treatment of some forms of breast cancer.

(Burnham Institute) Burnham Institute for Medical Research today announced that scientists have created a peptide that binds to Bcl-2, a protein that protects cancer cells from programmed cell death, and converts it into a cancer cell killer.

The research, which was published as the featured article in the Oct. 7 edition of Cancer Cell, may lead to new cancer treatments.

(Agency for Science, Technology and Research (A*STAR), Singapore) The absence or inactivation of the RUNX3 gatekeeper gene paves the way for the growth and development of colon cancer, Singapore scientists report in the September issue of the journal Cancer Cell.

Previous studies have shown that RUNX3 plays a role in gastric, breast, lung and bladder cancers.

(Helmholtz Association of German Research Centres) The effective treatment of many forms of cancer continues to pose a major problem for medicine.

Many tumors fail to respond to standard forms of chemotherapy or become resistant to the medication. Scientists at the Helmholtz Center for Infection Research in Braunschweig, the Hannover Medical School and Leibniz-Universität in Hanover have now discovered a chemical mechanism with which a natural substance -- argyrin -- destroys tumors.

Today, the researchers publish their findings in the renowned scientific journal Cancer Cell.

(Yale University) Metastasis, the spread of cancer throughout the body, can be explained by the fusion of a cancer cell with a white blood cell in the original tumor, according to Yale School of Medicine researchers, who say that this single event can set the stage for cancer's migration to other parts of the body.

Researchers at the University of Pennsylvania School of Medicine and Abramson Cancer Center reported today at the annual meeting of the American Association for Cancer Research that combining two targeted therapies overcomes treatment resistance in liver cancer cell lines.

Researchers at Jefferson's Kimmel Cancer Center in Philadelphia have shown that they can effectively kill prostate cancer cells in both the laboratory and in experimental animal models by blocking a signaling protein that is key to the cancer's growth.

The work proves that the protein, Stat5, is both vital to prostate cancer cell maintenance and that it is a viable target for drug therapy.